Fig. 1: Synergistic reduction of cell viability and enhanced BOK and NOXA expression by combined treatment with ABT-199 and BZB. | Cell Death & Disease

Fig. 1: Synergistic reduction of cell viability and enhanced BOK and NOXA expression by combined treatment with ABT-199 and BZB.

From: The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA

Fig. 1

a, b RD, SW982, and corresponding patient-derived tumor cells were incubated with the indicated concentrations of ABT-199 and/or BZB for 48 h. Cell viability was assessed by CellTiter-Glo Luminescent assay and normalized to the DMSO vehicle control. Drug interaction and synergisms were analyzed by calculation of the combination index (CI) using CompuSyn software. c Microscopic assessment of RD and SW982 shows only marginal numbers of floating (dead) cells 24 h after incubation with 5 nM BZB or 15 µM ABT-199 alone. In contrast, ABT-199/BZB massively induces cell death. d RD and SW982 cells were incubated in the absence (ctrl) or presence of 5 nM BZB, 15 µM ABT-199, or both for 8 h in the presence of Q-VD-OPh, before expression of the indicated proteins was analyzed by western blotting. Asterisk represents identical GAPDH blot because identical membrane was probed.

Back to article page